Table 7.

Comparison of psychological disorders during follow-up in statin users (≥ = 2 years) and non-users

	OR	95%CI		p-value
All patients cohort* (statin users = 12006 patients, non-users = 32623 patients)
Psych1 (schizophrenia/other psychosis)	0.87	0.76	1.02	0.09
Psych2 (depression / bipolar disorder)	1.15	1.05	0.97	0.2
Psych3 (all psychological disorders)	1.06	0.99	1.13	0.1
Patients with no Charlson comorbidity† (statin users = 5172 patients, non-users = 27400 patients)
Psych1 (schizophrenia/other psychosis)	0.88	0.69	1.12	0.3
Psych2 (depression / bipolar disorder)	1.03	0.93	1.15	0.5
Psych3 (all psychological disorders)	1.04	0.96	1.13	0.4
Patients with no psychological disorders at baseline‡ (statin users = 10095 patients, non- users = 28861 patients)
Psych1 (schizophrenia/other psychosis)	0.85	0.7	1.03	0.1
Psych2 (depression / bipolar disorder)	1.01	0.9	1.11	0.9
Psych3 (all psychological disorders)	1.05	0.98	1.12	0.2

^*Adjusting for age, gender, statin use, all comorbid conditions as in table 2, total Charlson comorbidity score, obesity, smoking, alcohol use, illicit drug use, psychological disorders at baseline, vision defects/blindness, number of all admissions in baseline period, number of all outpatients medical encounters in the baseline period, and use of different classes of medications as listed in table 1.

^†adjusting for the same factors mentioned earlier except for Charlson comorbidity total score and its components.

^‡adjusting for the same factors mentioned in “all patients cohort” except for “psychological disorders at baseline” covariate.